Nitec Pharma AG, a Swiss drug company focused on the treatment of chronic inflammatory diseases, has raised approximately $26 million in Series B funding. NGN Capital led the deal, and was joined by return backers Atlas Venture and Global Life Science Ventures.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
